These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36923080)

  • 21. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
    Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
    JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.
    Chen X; Nie J; Dai L; Hu W; Zhang J; Han J; Ma X; Tian G; Han S; Wu D; Wang Y; Long J; Zhang Z; Fang J
    Front Oncol; 2021; 11():607531. PubMed ID: 33747922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.
    Li B; Jiang C; Pang L; Zou B; Ding M; Sun X; Yu J; Wang L
    Front Immunol; 2021; 12():627197. PubMed ID: 33859637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study.
    Zhou C; Wang Z; Fu C; Tao H; Liu C
    Ann Transl Med; 2023 Feb; 11(3):157. PubMed ID: 36846007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience.
    Sun F; Wang D; Liu A; Wang T; Zhang D; Yao H; Sun K; Zhou Z; Lu G; Wu J
    Front Pharmacol; 2022; 13():837499. PubMed ID: 35370654
    [No Abstract]   [Full Text] [Related]  

  • 30. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
    JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis.
    Xiao BY; Lin GH; Zhao YX; Wang BC
    Transl Cancer Res; 2020 Jun; 9(6):3804-3818. PubMed ID: 35117748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations.
    Yang J; He X; Lv Q; Jing J; Shi H
    Front Pharmacol; 2019; 10():726. PubMed ID: 31312140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.